

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



Applicant:

Chen CHERMESH et al

Serial No.:

10/522,758

Filed:

October 18, 2005

For:

SIM2 POLYPEPTIDES AND POLYNUCLEOTIDES

AND USES OF EACH IN DIAGNOSIS AND TREATMENT OF OVARIAN, BREAST AND

**LUNG CANCERS** 

Examiner:

HARRIS, ALANA M

Group Art Unit: 1643

Attorney

§ §

\$ \$ \$ \$ \$ \$ \$ \$

Docket: 29225

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## INFORMATION DISCLOSURE STATEMENT

Sir:

Enclosed is a PTO Form 1449 which lists citations which may be material to the patentability and examination of the above identified application. Also enclosed are copies of the references cited. These are submitted in compliance with the duty of disclosure defined in 37 CFR 1.56. The Examiner is requested to make these citations of official record in this application.

This Information Disclosure Statement under 37 CFR 1.56 is not to be construed as a representation that a search has been made, that additional matter which is material to the examination of this application does not exist, or that any or more of these citations constitutes prior art.

> Respectfully submitted, Moznika

Martin D. Moynihan

Registration No. 40,338

Dated: August 8, 2006

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

Complete if Known

U.S.Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE rk Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)						tion Number	22,758		
						Filing Date October 18, 2005  First Named Inventor Chen CHERMESH et al  Art Unit 1643		per 18, 2005	
								CHERMESH et al	$\dashv$
				Examin	er Name	HARRIS, ALANA M			
Sheet 1			of	2	Attorne	y Docket Number	2922	29225	
			U.S. I	PATENT	DOCUM	ENTS			$\exists$
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publicati MM-DD	on Date	Name of Patentee or Applicant of Cited Document		Pages, Columns, Lines, Where Relevant Passages or Relevant		
	ļ	Number-Kind Code <sup>2 (if known)</sup>						Figures Appear	
									$\dashv$
									$\dashv$
			ļ						
			ļ	······································					_
	<u> </u>	¥							
									_
	<u> </u>								
			1		L				
		1,	FOREIC	N PATE	NT DOC	UMENTS			
Examiner Initials*	Cite No. 1	Foreign Patent Documents  Country Code <sup>3-</sup> Number <sup>4-</sup> Kind Code <sup>5</sup> (if known)  PCT WO 02/12565			ation Date	Name of Patentee or Applicant of Cited Document Narayanan		Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т
				MM-E	D-YYYY				6
	1			02-14-	2002				
-0							<del>.</del>		_
									ŀ
							·····		-
						-			$\vdash$
Examine	er	<u> </u>	-	1		Date		•	•
Signature						Con	sidered		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Senter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language

Signature

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

MATRAB Complete if Known Substitute for form 1449A/PTO Application Number 10/522,758 October 18, 2005 Filing Date INFORMATION DISCLOSURE First Named Inventor Chen CHERMESH et al STATEMENT BY APPLICANT Group Art Unit 1643 **Examiner Name** HARRIS, ALANA M (use as many sheets as necessary) 2 Attorney Docket Number Sheet 2 OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Cite Examiner item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s),  $T^2$ No.1 Initials publisher, city and/or country where published. 2 DeYoung et al. "Indentification of Down's Syndrome Critical Locus Gene SIM2-s as A Drug Therapy Target for Solid Tumors", PNAS, 100(8): 4760-4765, 2003. 3 Ratan "Mining Genome Databases for Therapeutic Gold: SIM2 is a Novel Target for Treatment of Solid Tumors", Trends in Pharmacological Sciences, 24(10): 508-510, 4 DeYoung et al. "Down's Syndrome-Associated Single Minded 2 Gene as a Pancreatic Cancer Drug Therapy Target", Cancer Letters, 200: 25-31, 2003. Younes et al. "Labelled Oligonucleotides as Radiopharmaceuticals: Pitfalls, Problems 5 and Perspectives", Current Pharmaceutical Designs, 8(16): 1451-1466, 2002. 6 Sazani et al. "Modulation of Alternative Splicing by Antisense Oligonucleotides", Progress in Molecular and Subcellular Biology, 31: 217-239, 2003. 7 Chrast et al. "Cloning of Two Human Homologs of the Drosophila Single-Minded Gene SIM1 on Chromosome 6q and SIM2 on 21q Within the Down Syndrome Chromosomal Region", Genome Research, 7(6): 615-624, 1997. Probst et al. "Two Murine Homologs of the Drosophila Single-Minded Protein That 8 Interact With the Mouse Aryl Hydrocarbon Receptor Nuclear Translocator Protein", The American Society of Biochemistry and Molecular Biology, 272(7): 4451-4457, 1997.

Signature	Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1. Applicant's unique citation designation number (optional). 2. Applicant is to place a check mark here if English language Translation is attached.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.